✦ LIBER ✦

99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin’s lymphoma

✍ Scribed by Susan F. Vervoordeldonk; Janneke Heikens; Wim T. Goedemans; Pauline A. Merle; A. E. G. K. von dem Borne; Eric A. van Royen; Ineke C. M. Slaper-Cortenbach; Rien H. J. van Oers

Book ID: 105968123
Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 527 KB
Volume: 42
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620050285

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

CD20-specific antibody-targeted chemothe

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

✍ John F. DiJoseph; Maureen M. Dougher; Douglas C. Armellino; Lyka Kalyandrug; Art 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 341 KB

Clinical trials of a mouse-human chimeri

Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan

✍ Kensei Tobinai 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 130 KB

Treatment of relapsed B-cell non-Hodgkin

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

✍ van der Kolk, L E; Grillo-López, A J; Baars, J W; van Oers, M H J 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB